Regional Comprehensive Cancer Centers in Poland as reference units improving prognosis in cancer patients - Example of the Lower Silesian Cancer Comprehensive Center in Wroclaw [Znaczenie Regionalnych Ośrodków Onkologicznych w Polsce jako jednostek referencyjnych w poprawie rokowania chorych na nowotwory - Przykład Dolnośla̧skiego Centrum Onkologii we Wrocławiu]
Bebenek M.,I Oddzial Chirurgii Onkologicznej |
Sedziak T.,I Oddzial Chirurgii Onkologicznej |
Kapturkiewicz B.,I Oddzial Chirurgii Onkologicznej |
Blaszczyk J.,Zaklad Epidemiologii i Dolnoslaski Rejestr Nowotworow
Nowotwory | Year: 2011
Introduction: The role of Regional Comprehensive Cancer Centers as units responsible for complex cancer treatment was not defined in Poland thus far. Consequently, either allocation of financial resources or treatment qualification of cancer patients at various clinical stages is mostly random. The aim of this study was to define the role played in Polish oncology by regional comprehensive cancer centers. This goal was fulfilled based on the experiences of the Regional Comprehensive Cancer Center in Wroclaw (RCCC). Results: During the study period, the fraction of Lower Silesian patients with rectal, breast and ovarian cancer and malignant melanoma which were operated on at RCCC ranged from slightly above 36% to less than 60%. No significant differences in clinical stage distributions were observed between the patients of RCCC and those treated at other Lower Silesian hospitals. However, for all locations analyzed the fractions of 5-year relative survivals were significantly higher in patients treated at RCCC compared to those from other Lower Silesian hospitals or in Poland overall. Conclusion: These results give another argument in a discussion on the rules of financing Polish oncology, and particularly state for implementing separate rules of financial allocation for reference centers specialized in oncologic surgery and general surgery centers.
Bebenek M.,I Oddzial Chirurgii Onkologicznej
Nowotwory | Year: 2015
Colorectal cancer is the second most frequent type of solid tumour and the second leading cause of mortality in oncological patients. Optimisation of surgical techniques results in a gradual increase in the percentage of curative resections of colorectal tumours. Nevertheless, a considerable fraction of patients (30-50%) suffer from recurrent colorectal cancer. This justifies intensive follow-up after treatment. Beneficial effects of such approach are confirmed by the results of clinical trials and meta-analyses. Follow-up should be particularly intensive during the initial three years after treatment, and should be continued for at least five years. Vital components of the follow-up are physical examination, colonoscopy, imaging of the abdominal cavity and chest, and determination of serum level of carcinoembryonic antigen (CEA). © Polskie Towarzystwo Onkologiczne.